Sg Americas Securities, LLC Apellis Pharmaceuticals, Inc. Transaction History

Sg Americas Securities, LLC

$27.6 Billion
Q3 2024

A detailed history of Sg Americas Securities, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 23,469 shares of APLS stock, worth $777,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,469

Previous 107,561 78.18%

Holding current value

$777,762

Previous $4.13 Million 83.59%

% of portfolio

0.0%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 03, 2024	SELL	$28.84 - $41.15 $2.43 Million - $3.46 Million	-84,092 Reduced 78.18%	23,469 $677,000
Q2 2024 Jul 12, 2024	BUY	$38.07 - $59.71 $2.29 Million - $3.58 Million	60,026 Added 126.28%	107,561 $4.13 Million
Q1 2024 May 06, 2024	SELL	$55.39 - $72.47 $75,662 - $98,994	-1,366 Reduced 2.79%	47,535 $2.79 Million
Q4 2023 Jan 12, 2024	SELL	$37.14 - $64.82 $4.67 Million - $8.15 Million	-125,668 Reduced 71.99%	48,901 $2.93 Million
Q3 2023 Oct 13, 2023	BUY	$23.65 - $89.22 $1.74 Million - $6.55 Million	73,458 Added 72.65%	174,569 $6.64 Million
Q2 2023 Jul 10, 2023	BUY	$76.68 - $93.31 $6.9 Million - $8.4 Million	90,048 Added 813.96%	101,111 $9.21 Million
Q1 2023 Apr 28, 2023	SELL	$46.59 - $66.96 $946,662 - $1.36 Million	-20,319 Reduced 64.75%	11,063 $730,000
Q4 2022 Feb 02, 2023	BUY	$43.24 - $61.04 $152,204 - $214,860	3,520 Added 12.63%	31,382 $1.62 Million
Q3 2022 Oct 31, 2022	SELL	$44.76 - $69.66 $1.07 Million - $1.66 Million	-23,894 Reduced 46.17%	27,862 $1.9 Million
Q2 2022 Jul 29, 2022	BUY	$35.07 - $59.21 $1.67 Million - $2.82 Million	47,611 Added 1148.64%	51,756 $2.34 Million
Q1 2022 Apr 29, 2022	SELL	$35.46 - $54.12 $6.16 Million - $9.39 Million	-173,589 Reduced 97.67%	4,145 $211,000
Q4 2021 Feb 07, 2022	SELL	$30.74 - $49.16 $193,047 - $308,724	-6,280 Reduced 3.41%	177,734 $8.4 Million
Q3 2021 Nov 01, 2021	BUY	$31.4 - $69.84 $4.99 Million - $11.1 Million	159,061 Added 637.44%	184,014 $6.07 Million
Q2 2021 Aug 12, 2021	BUY	$40.9 - $64.9 $292,107 - $463,515	7,142 Added 40.1%	24,953 $1.58 Million
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $614,856 - $864,867	15,070 Added 549.8%	17,811 $764,000
Q4 2020 Feb 04, 2021	SELL	$30.79 - $57.2 $991,376 - $1.84 Million	-32,198 Reduced 92.15%	2,741 $157,000
Q3 2020 Nov 09, 2020	BUY	$25.89 - $33.65 $779,496 - $1.01 Million	30,108 Added 623.23%	34,939 $1.05 Million
Q2 2020 Jul 20, 2020	SELL	$24.8 - $38.49 $166,060 - $257,729	-6,696 Reduced 58.09%	4,831 $158,000
Q1 2020 Apr 30, 2020	BUY	$17.91 - $44.33 $52,028 - $128,778	2,905 Added 33.69%	11,527 $309,000
Q4 2019 Jan 28, 2020	SELL	$22.1 - $30.8 $1.26 Million - $1.76 Million	-57,187 Reduced 86.9%	8,622 $264,000
Q3 2019 Nov 04, 2019	BUY	$24.09 - $32.18 $1.59 Million - $2.12 Million	65,809 New	65,809 $1.59 Million
Q2 2019 Jul 29, 2019	SELL	$18.0 - $25.34 $103,716 - $146,009	-5,762 Closed	0 $0
Q1 2019 Apr 29, 2019	BUY	$12.81 - $19.82 $73,811 - $114,202	5,762 New	5,762 $112,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Account

Sg Americas Securities, LLC Apellis Pharmaceuticals, Inc. Transaction History